- Home
- VMD vs RIGL Comparison
VMD vs RIGL Comparison
Compare VMD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMD | RIGL |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.2M | 564.7M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | VMD | RIGL |
|---|---|---|
| Price | $9.84 | $30.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | 236.5K | ★ 407.1K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.14 | ★ 1867.68 |
| EPS | 0.06 | ★ 0.44 |
| Revenue | $270,280,000.00 | ★ $294,282,000.00 |
| Revenue This Year | $17.88 | N/A |
| Revenue Next Year | $14.98 | $12.75 |
| P/E Ratio | $167.17 | ★ $68.14 |
| Revenue Growth | 20.52 | ★ 64.15 |
| 52 Week Low | $5.93 | $18.14 |
| 52 Week High | $10.18 | $52.24 |
Technical Indicators
Market Signals| Indicator | VMD | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 56.95 |
| Support Level | $9.22 | $27.98 |
| Resistance Level | $10.04 | $32.17 |
| Average True Range (ATR) | 0.36 | 1.69 |
| MACD | 0.05 | 0.18 |
| Stochastic Oscillator | 85.44 | 68.78 |
Price Performance
Historical ComparisonAbout VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.